Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Grabbe

Showing results (311-320 of 325) with videos related to

Pageof 33
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Plos One|January 24, 2013
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkCaroline J Voskens, Simone M Goldinger, Carmen Loquai, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
Journal for Immunotherapy of Cancer|April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Nature|July 6, 2017
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerUgur Sahin, Evelyna Derhovanessian, Matthias Miller, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
Pageof 33

Showing results (311-320 of 325) with videos related to

Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Plos One|January 24, 2013
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkCaroline J Voskens, Simone M Goldinger, Carmen Loquai, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
Journal for Immunotherapy of Cancer|April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Nature|July 6, 2017
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerUgur Sahin, Evelyna Derhovanessian, Matthias Miller, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
Pageof 33